NCT02489903 2025-03-17RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)EpicentRx, Inc.Phase 2 Completed139 enrolled 14 charts
NCT02164461 2024-05-20Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical CancerAdvaxis, Inc.Phase 1 Completed12 enrolled 18 charts
NCT00412880 2022-06-22BI 2536 Second Line Monotherapy in SCLCBoehringer IngelheimPhase 2 Completed23 enrolled 10 charts
NCT02034123 2019-12-06Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung CarcinomaGlaxoSmithKlinePhase 1 Terminated29 enrolled 34 charts
NCT00537511 2019-11-19A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and EtoposideCelgenePhase 1/2 Terminated22 enrolled 13 charts
NCT00298896 2018-07-26Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung CancerSunesis PharmaceuticalsPhase 2 Completed55 enrolled 10 charts
NCT00447421 2009-10-28A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and RadiotherapyEli Lilly and CompanyPhase 1/2 Terminated9 enrolled 6 charts